Physicians' Academy for Cardiovascular Education
Member

BET Inhibition

BET bromodomain inhibition is an epigenetic mechanism that can turn disease-causing genes off, returning them to a healthier state. BET inhibitors selective for BRD4-BD2 are currently tested in clinical trials with potentially important benefits for patients with diseases such as cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease.

Investigational epigenetic therapy lowers incidence of MACE in phase 2b study

Nov. 15, 2016 - AHA 2016, New Orleans, LA, USA - Dr. Norman Wong, Calgary, AB, Canada

Meeting Impression: A novel approach for high CV risk patients with diabetes: The potential for epigenetics

Sep. 6, 2016 - news

The high risk diabetes patient with cardiovascular disease: What else can we target to reduce cardiovascular risk?

Aug. 28, 2016 - news

Investigational epigenetic therapy lowers incidence of MACE in phase 2b study

Nov. 15, 2016 - AHA 2016, New Orleans, LA, USA - Dr. Norman Wong, Calgary, AB, Canada
Epigenetic apabetalone or RVX-208 that alters chromatin structure and gene activity gave clinical benefit in phase 2 study.

AHA 2016 The orally active epigenetic drug RVX-208 or apabetalone that alters gene activity by modifying chromatin structure, lowered the incidence of MACE in a phase 2b study. This effect could not entirely be attributed to an effect on HDL, explains dr. Norman Wong.

Meeting Impression: A novel approach for high CV risk patients with diabetes: The potential for epigenetics

Sep. 6, 2016 - news
A novel Approach for high CV risk patients with diabetes: The potential for epigenetics and apabetalone

A Meeting Impression from a EBAC accredited satellite symposium held at ESC 2016 in Rome that explored a novel approach to reduce residual CV risk, namely BET inhibition

The high risk diabetes patient with cardiovascular disease: What else can we target to reduce cardiovascular risk?

Aug. 28, 2016 - news

At the 'A novel approach for high cv risk patients with diabetes: the potential of epigenetics' symposium, held at the ESC Congress 2016 in Rome, Kausik Ray spoke about therapeutic targets to further lower CV risk.

Understanding BET inhibition as a novel pathway for cardiovascular risk modulation

Jorge Plutzky, MD - Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Aug. 28, 2016 - Jorge Plutzky, MD - Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

At the 'A novel approach for high cv risk patients with diabetes: the potential of epigenetics' symposium, held at the ESC Congress 2016 in Rome, Jorge Plutzky spoke about BET inhibition as a nover pathway for CV risk reduction.

Effects of novel BET-inhibitor on the HDL lipidome and glucose metabolism

May 26, 2016 - Siebel AL et al., J. metabol. 2016

RVX-208 affected HDL lipid composition and HDL particle size distribution and modulated glucose metabolism in prediabetic individuals.

A novel epigenetic approach to reduce atherosclerosis

Nov. 11, 2015 - Nikolic D et al., Expert Opin Investig Drugs. 2015

RVX-208 is an investigational BET bromodomain inhibitor that upregulates apoA-I gene transcription, leading to increased HDL-levels and larger HDL particles. This review summarises currently available data.